- Home
- CNTX vs IMA Comparison
CNTX vs IMA Comparison
Compare CNTX & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTX | IMA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 92.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTX | IMA |
|---|---|---|
| Price | $1.08 | $6.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $5.40 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 430.5K | 59.4K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $6.19 |
| 52 Week High | $1.61 | $18.00 |
Technical Indicators
Market Signals| Indicator | CNTX | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.30 | N/A |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.13 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 28.87 | 0.00 |
Price Performance
Historical ComparisonAbout CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.